ArticleOpen access20255citation· Semantic Scholar
Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model
ClinicoEconomics and Outcomes Research · vol. Volume 17 · 217-232
ofatumumabteriflunomiderelapsing-remitting multiple sclerosiscost-effectiveness
